Citigroup’s HCW Biologics HCWB Stock Holding History

Citigroup’s Portfolio HCWB Stock Details HCWB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$879	Buy	+514	New	+$1.54K	﹤0.01%	5550
2026 Q2	–	Sell	-1,755	Closed	-$3.79K	–	5955
2026 Q1	$3.79K	Buy	+1,755	New	+$9.08K	﹤0.01%	5314
2025 Q4	–	Sell	-52	Closed	-$884	–	5971
2025 Q3	$1.15K	Buy	+52	New	+$1.36K	﹤0.01%	5606
2025 Q2	–	Sell	-59	Closed	-$3.96K	–	5756
2025 Q1	$3.96K	Buy	+59	New	+$5.19K	﹤0.01%	5299

Other funds holding HCWB

Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Golden State Wealth Management Santa Ana, California $1.1B AUM 19.2% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $83.6B AUM 19.78% 1-Year Est. Return

Caitong International Asset Management Hong Kong $1.04B AUM 150.26% 1-Year Est. Return

Citigroup's HCWB Position: Q3 2026 in Review

Citigroup opened a new position in HCW Biologics (HCWB) in Q3 2026: 514 shares worth $879. The stake represents ﹤0.01% of the portfolio and ranks #5550 among its holdings. This is a return to the name: Citigroup previously reported a position in HCWB as recently as Q1 2026.

Citigroup first reported a position in HCWB in Q1 2025 and has held it in 4 quarters since. The position peaked at $3.96K in Q1 2025. 8 funds tracked by Wall St. Rank hold HCWB as of Q3 2026.

Citigroup held 514 shares of HCW Biologics worth $879 as of Q3 2026.
HCW Biologics was a new Citigroup position in Q3 2026.
HCW Biologics made up ﹤0.01% of Citigroup's portfolio in Q3 2026, its #5550 holding.
Citigroup first reported a position in HCW Biologics in Q1 2025 and has held it in 4 quarters since.
Citigroup's HCW Biologics position peaked at $3.96K in Q1 2025.
8 funds tracked by Wall St. Rank held HCW Biologics as of Q3 2026.

Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.